Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? - Wikidata - wikimedia - TriplyDB

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

http://www.wikidata.org/entity/Q38107347

about

Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.Treatment Approach to Patients With Severe Insulin Resistance.Insulin therapy in people with type 2 diabetes: opportunities and challenges?Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.A review of gliptins for 2014.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes.

P2860

Q33785141-1014E998-1AFC-4F9B-82DC-737D6BB51BC4 Q34169097-AD198FB2-1680-47FE-9E69-3C2D1393BE7D Q35841565-0F5FED47-2A2B-4D91-9AF7-452CB5BF71EA Q35887463-A4FF2956-8F5E-45B5-8CD7-B6D5C6D7EFEA Q36803134-31934089-6878-4998-AA9B-C0F95E31E27B Q37461707-65628491-A555-4603-A778-E8D27EB5AB40 Q37468458-D958577F-BB6C-4F16-8860-31B691E42BEC Q37598881-51F2146A-C804-4071-A919-2D37C8F05BC6 Q38266290-0C703325-9119-40B8-9BC5-6AD777113A18 Q38412153-61D90AB7-8E04-4BD9-A1E0-11633F9C98E9 Q38452890-711F6256-D22A-4A44-A956-F68F2DB86E21 Q51283779-E852A07C-08EB-44E9-A8E8-295607EAFC66

P2860

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

http://www.wikidata.org/entity/Q38107347

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combination therapy with DPP-4 ...... ellitus: what is the evidence?

@en

type

label

Combination therapy with DPP-4 ...... ellitus: what is the evidence?

@en

prefLabel

Combination therapy with DPP-4 ...... ellitus: what is the evidence?

@en

P1433

Q38107347-760E5D61-AFC4-43C2-B7D2-CDD262631465

P1476

Q38107347-B9A2D86E-6F3B-490F-893E-479C791878EC

P2093

Q38107347-1292AF84-7CFD-4312-AE77-475B579C0079

Q38107347-2F8137BE-9C7D-4F48-A9EA-8CC25F0D57FE

Q38107347-77728CC2-C5AB-4000-A253-3C98E81625B0

P2860

Q38107347-01FCF553-2610-4162-9096-A291EDCB6BB8

Q38107347-040DFF2B-E588-4B2B-ADA4-4B8135489490

Q38107347-0A4D5E36-6D03-4214-BEB3-6CB978406098

Q38107347-0AC00F53-A229-4030-B629-1508FE2A6DAF

Q38107347-0FF5D5C4-1ADD-4A37-BCEF-778851AAD2B8

Q38107347-16D1173B-61C6-480E-B124-63A38D84AC47

Q38107347-1CFE949E-2955-4CF7-8AF1-6BB3405901CA

Q38107347-1F54283D-E6E4-47ED-BB4F-1C0F98BA58AE

Q38107347-2B4A1CC3-ADB8-4384-AACB-7AE9BDE2709F

Q38107347-2F2BE58E-6792-4844-987D-BE1400C701EF

P304

Q38107347-2A6972EF-4543-429B-9C93-051F9F30D4B6

P31

Q38107347-B8D8FEA4-CEB5-4747-B73F-BDC6C3729B1E

P356

Q38107347-3853A51F-B258-457F-BFC9-9FEBC7BE5F5A

P407

Q38107347-B3D2B851-4FF7-46A7-A579-4C337708ED3C

P433

Q38107347-016CA0C8-67A3-452E-A7CA-59C9D2D946CC

P478

Q38107347-FF2F22A7-667F-460E-A5D2-1A7A5194546D

P577

Q38107347-E8D33E5B-666F-417C-8CBB-505963020557

P5875

Q38107347-B036A642-638E-43B3-8999-CB47A58E501E

P698

Q38107347-5019C9C5-2023-4995-B855-CFC2B58B20E5

P921

Q38107347-54BB2682-61A1-40E3-A2F8-8D9039EC8CE7

P356

HP.2013.04.1059

P1433

Hospital Practice

P1476

Combination therapy with DPP-4 ...... ellitus: what is the evidence?

@en

P2093

Anja Schweizer

http://www.w3.org/2001/XMLSchema#string

Bernard Charbonnel

http://www.w3.org/2001/XMLSchema#string

Sylvie Dejager

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Combination therapies with insulin in type 2 diabetes.

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

Hypoglycaemia in Type 2 diabetes.

Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

P304

93-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/HP.2013.04.1059

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236915257

http://www.w3.org/2001/XMLSchema#string

P698

23680741

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes